MiniMed Stock Jumps on Q1 Revenue Beat and Raised Full-Year Guidance

MiniMed shares surged in morning trading after the diabetes technology firm reported fiscal first-quarter revenue that beat its own expectations and raised its full-year sales guidance, signaling strong commercial momentum. The stock climbed 6.8% on the news, defying a broader market downturn to reach a new 52-week high.

Strong Sales Growth Exceeds Expectations

The company announced net sales of $843 million for its fiscal first quarter of 2027, representing year-over-year organic growth of approximately 15.8%. This performance was driven by accelerating commercial traction in the U.S., where revenue grew 13%, and continued international expansion, with organic revenue up roughly 17%.

According to the earnings release, the results surpassed internal forecasts and reflected widespread demand for the company's automated insulin delivery systems and an increase in sensor attachment rates.

Upgraded Outlook and Pipeline Wins

Buoying investor sentiment, MiniMed lifted its financial outlook for the full fiscal year 2027. Management now projects organic revenue growth of approximately 10.5%, an increase from its prior target of about 10%.

Ad

The company also reaffirmed its adjusted EBITDA margin guidance of approximately 16%, a key metric suggesting that the firm is balancing growth with cost discipline. The positive report was further supported by a series of key pipeline achievements:

• The MiniMed Flex system received CE Mark approval in Europe well ahead of its year-end target.
• Enrollment was completed for the U.S. pivotal trial of its Vivera fully-closed loop algorithm.
• It secured Investigational Device Exemption (IDE) approval for its next-generation extended wear sensor.

Market Reaction

Investors reacted positively to the combination of a revenue beat, raised guidance, and pipeline milestones, pushing shares to a new 52-week high of $21.86 during the session.

The stock's performance stood in sharp contrast to the wider market, with the S&P 500 and Nasdaq Composite declining 0.6% and 1.0%, respectively, during the same period. This underscores that the move was driven entirely by company-specific catalysts rather than broader market sentiment.